Welcome to the latest edition of NORMLs Weekly Legislative Roundup
Lets talk about some new state-level developments. The Maine House of Representatives and Senate overrode Gov. Paul LePages R veto of marijuana legalization implementation legislation this week. The enactment of the legislation establishes a framework for the retail sale of marijuana to adults, but also amends numerous provisions of the 2016 voter-approved measure including those specific to home grow limits and taxation.
The New Approach Missouri medical cannabis campaign submitted 372,483 petition signa....
California Committee Approves Measure to Make Employers Treat Medical Marijuana Like Prescription Drugs
Californias Assembly Labor and Employment Committee has given approval to Assembly Bill 2069, which is designed to end employer discrimination against medical marijuana patients.
The legislative proposal titled the Medical Cannabis Worker Protections Act would force employers to treat medical marijuana the same way they do legal prescription drugs such as but not limited to opioids. Employers would be required to give reasonable accommodation to medical marijuana patients under the states Fair Employment and Housing Act.
The legislation, filed by Asemblymember Rob Bonta D along with Asemblymember Bill Quick D, was passed last week by the Assembly Labor and Employment Committee in a 5 to 1 vote.
The bill exempts employers who may be subject to f....
Bipartisan Legislation Introduced To Facilitate Medical Cannabis Trials For Veterans
United States Rep. Timothy Waltz D-MN, along with over 30 bipartisan co-sponsors, has introduced legislation, HR 5520: The VA Medicinal Cannabis Research Act of 2018, to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans.
The legislation states: In carrying out the responsibilities of the Secretary of Veterans Affairs, the Secretary may conduct and support research relating to the efficacy and safety of forms of cannabis on the health outcomes of covered veterans diagnosed with chronic pain, post-traumatic str....
U.S. Senate Minority Leader Announces Measure to Decriminalize Marijuana
Senate Minority Leader Chuck Schumer D announced today that he will soon be introducing legislation that would decriminalize marijuana across the United States.
In an interview with VICE News Schumer called the legislation long overdue, and said that too many people have been effected by the plants prohibiton.
Ill be introducing legislation to decriminalize marijuana at the federal level from one end of the country to the other, said Schumer, who is the leading Democrat in the Senate. Schumers announcement comes just weeks after the Senate Majority Leader Mitch McConnell R announced legislation that would legalize hemp.
Ive seen too many peoples lives ruined because they had small amounts of marijuana and served time in jail, muc....
GOP Lawmaker: Trump Administration Pledges Non-Interference In Legal Marijuana States
Republican Senator Cory Gardner CO says that he has received a verbal commitment from President Donald Trump specifying that the administration will not take action to disrupt marijuana markets in states that legally regulate the substance.
Since the campaign, President Trump has consistently supported states rights to decide for themselves how best to approach marijuana, Gardner told the Associated Press. Late Wednesday, I received a commitment from the President that the Department of Justices rescission of the Cole memo will not impact Colorados legal marijuana industry....
Feds Now Accepting Public Comments on Potential Rescheduling of Marijuana
Starting today, the federal government is accepting public comments regarding the potential rescheduling of marijuana as a schedule 1 controlled substances which puts it alongside drugs such as heroin.
In response to the United Nations World Health Organization announcing that they will soon review the current international classification of marijuana, the U.S. Food and Drug Administration FDA is themselves starting a review, and are asking interested persons to submit comments regarding the potential rescheduling of marijuana. The public comment period will be open from today, to April 23.
The FDA is seeking input on the abuse potential, actual abuse, medical usefulness, trafficking and impact of scheduling changes on availability for medical use of marijuana and its c....
Medical Marijuana`s `Catch-22`: Limits On Research Hinder Patient Relief
Marisa Taylor Melissa Bailey
By the time Ann Marie Owen, 61, turned to marijuana to treat her pain, she was struggling to walk and talk. She was also hallucinating.
For four years, her doctor prescribed a wide range of opioids for transverse myelitis, a debilitating disease that caused pain, muscle weakness and paralysis.
The drugs not only failed to ease her symptoms, they hooked her.
When her home state of New York legalized marijuana for the treatment of select medical ailments, Owens decided it was time to swap pills for pot. But her doctors refused to help.
``Even though medical marijuana is l....
Google and Facebook wont advertise marijuana, even where its legal
Rachel Siegel The Washington Post
As the cannabis industry grows, generating an estimated $10 billion in annual sales, states are increasingly approving medical marijuana programs and passing adult-use laws.
But for marketing agencies, marijuana dispensaries and cannabis brands, advertising the pot brings its own hurdles.
Online platforms with prime advertising space like Facebook and Google do not allow drug, or drug-related promotions on their sites, leaving a large share of marijuana advertising to blogs and podcasts, newsletters and print media. And while experts say Facebook and Google which control....
We make every effort to provide timely and accurate information, however we cannot guaranty the accuracy of these listings.
To correct a listing, please use the corrections link or contact the web master, Mark.
This web site contains no advertising. Listings in this directory are licensed business. Reviews and editorials are the opinion of the author only, not those of the National Cannabis Review.